Dabigatran etexilate (BioDeep_00000033363)

   

human metabolite blood metabolite


代谢物信息卡片


ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate

化学式: C34H41N7O5 (627.3169015999999)
中文名称: 达比加群酯
谱图信息: 最多检出来源 Homo sapiens(blood) 40%

分子结构信息

SMILES: CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1
InChI: InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)

描述信息

Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated.
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AE - Direct thrombin inhibitors
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C180619 - Direct Oral Anticoagulant
C78275 - Agent Affecting Blood or Body Fluid > C263 - Anticoagulant Agent > C173066 - Direct Thrombin Inhibitor
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
D006401 - Hematologic Agents > D000925 - Anticoagulants > D000991 - Antithrombins

同义名列表

12 个代谢物同义名

ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate; Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate; N-((2-(((4-(Aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine; Etexilate mesylate, dabigatran; Mesylate, dabigatran etexilate; Dabigatran etexilate mesylate; Dabigatran etexilic acid; Etexilate, dabigatran; Dabigatran etexilate; Dabigatran; BIBR 1048; Pradaxa



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Giuseppe Derosa, Manfredi Rizzo, Natale Daniele Brunetti, Riccardo Raddino, Mara Gavazzoni, Gianfranco Pasini, Giovanni Gaudio, Antonio Maggi, Angela D'Angelo, Luisa De Gennaro, Pamela Maffioli. ORal anticoaGulants in diAbetic and Nondiabetic patients with nOn-valvular atrial fibrillatioN (ORGANON). Journal of diabetes and its complications. 2023 08; 37(8):108512. doi: 10.1016/j.jdiacomp.2023.108512. [PMID: 37390799]
  • Zhen-Ling Deng, Wen-Ling Yang, Xin-Yue Zhao, Zi-Yong Tang, Dan-Xia Zheng, Yue Wang. Simultaneous subacute interstitial nephritis and anticoagulant-related nephropathy related to novel oral anticoagulants use. Renal failure. 2022 Dec; 44(1):30-33. doi: 10.1080/0886022x.2021.2014338. [PMID: 35086437]
  • Rachel Aakerøy, Charlotte L Stokes, Marija Tomić, Solfrid Hegstad, Ann Helen Kristoffersen, Hanne Ellekjær, Jan Schjøtt, Olav Spigset, Arne Helland. Serum or Plasma for Quantification of Direct Oral Anticoagulants?. Therapeutic drug monitoring. 2022 Aug; 44(4):578-584. doi: 10.1097/ftd.0000000000000956. [PMID: 35051972]
  • Jean Terrier, Frédéric Gaspar, Monia Guidi, Pierre Fontana, Youssef Daali, Chantal Csajka, Jean-Luc Reny. Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation. Clinical pharmacology and therapeutics. 2022 Aug; 112(2):353-363. doi: 10.1002/cpt.2649. [PMID: 35593020]
  • Shaughn Nalezinski. Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review. Laboratory medicine. 2022 Jul; 53(4):336-343. doi: 10.1093/labmed/lmab115. [PMID: 35073576]
  • Sajidah Alkhameys, Ravina Barrett. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021). Current medical research and opinion. 2022 Jul; 38(7):1081-1092. doi: 10.1080/03007995.2022.2078100. [PMID: 35582854]
  • Fathy Ibrahim Abd Allah, Ahmed Ali Almrasy, Ahmed Abdelhmaid, Osama A Abd-Elmegid, Akram Alkashlan, Abdul-Aziz M M El-Attar. Development and validation of a ultraperformance liquid chromatography-tandem mass spectrometry method for quantifying free and total dabigatran in human plasma: An application for a bioequivalence study. Biomedical chromatography : BMC. 2022 Jul; 36(7):e5382. doi: 10.1002/bmc.5382. [PMID: 35389511]
  • Dan Sly, Margaret Husted, Lynn McKeague, Tamara Everington. 'I just didn't want to trust it at all': Atrial fibrillation patient's treatment experience of rivaroxaban and warfarin. Journal of evaluation in clinical practice. 2022 06; 28(3):436-444. doi: 10.1111/jep.13628. [PMID: 34636130]
  • Maxime Delrue, Lucie Chevillard, Alain Stépanian, Alessandra Dragoni, Laurence Camoin-Jau, Sébastien Voicu, Isabelle Malissin, Nicolas Deye, Marc Gainnier, Virginie Siguret, Bruno Mégarbane. Case series of massive direct oral anticoagulant ingestion-Treatment and pharmacokinetics data. European journal of clinical investigation. 2022 Jun; 52(6):e13746. doi: 10.1111/eci.13746. [PMID: 35000196]
  • Tingting Zheng, Lulu Liu, Jiayi Liu, Zhengxiang Zhang. Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report. Journal of musculoskeletal & neuronal interactions. 2022 06; 22(2):296-300. doi: ". [PMID: 35642709]
  • Francesco Negro, Paolo Caravelli, Riccardo Morganti, Monica Casini, Lucia Ruocco, Armando Tripodi, Raffaele De Caterina. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Vascular pharmacology. 2022 06; 144(?):106994. doi: 10.1016/j.vph.2022.106994. [PMID: 35436607]
  • Gabriela Siedler, Kosmas Macha, Svenja Stoll, Johannes Plechschmidt, Ruihao Wang, Stefan T Gerner, Erwin Strasser, Stefan Schwab, Bernd Kallmünzer. Monitoring of direct oral anticoagulants plasma levels for secondary stroke prevention. Journal of thrombosis and haemostasis : JTH. 2022 05; 20(5):1138-1145. doi: 10.1111/jth.15677. [PMID: 35171533]
  • Zhu Zhu, Zhu Shen, Aiming Shi, Cunjin Su, Jiaojiao Mao, Hong Tao, Feng Xu, Zhanhong Hu, Jie Pan. Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation. Heart and vessels. 2022 May; 37(5):821-827. doi: 10.1007/s00380-021-01974-0. [PMID: 34694442]
  • Sophie C Dólleman, Stijn M Agten, Henri M H Spronk, Tilman M Hackeng, Mettine H A Bos, Henri H Versteeg, Anton Jan van Zonneveld, Hetty C de Boer. Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity. Journal of thrombosis and haemostasis : JTH. 2022 04; 20(4):996-1007. doi: 10.1111/jth.15642. [PMID: 35037739]
  • Vladimír Nosáľ, Andrea Petrovičová, Ingrid Škorňová, Tomáš Bolek, Jana Dluhá, Lucia Stančiaková, Štefan Sivák, Lucia Babálová, Gabriel Hajaš, Ján Staško, Peter Kubisz, Egon Kurča, Matej Samoš, Marián Mokáň. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study. European journal of clinical pharmacology. 2022 Apr; 78(4):557-564. doi: 10.1007/s00228-022-03280-8. [PMID: 35066599]
  • Maria Chiara Pacchiarini, Giuseppe Vizzini, Chiara Italiano, Enrico Fiaccadori, Giovanni Maria Rossi. Atheroembolic renal disease associated with dabigatran overdose. Journal of nephrology. 2022 04; 35(3):1053-1057. doi: 10.1007/s40620-021-01158-z. [PMID: 34727351]
  • Antonio González Pérez, Yanina Balabanova, María E Sáez, Gunnar Brobert, Luis A García Rodríguez. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom. International journal of cardiology. 2022 Apr; 352(?):165-171. doi: 10.1016/j.ijcard.2022.01.063. [PMID: 35122912]
  • Francis Flynn, Guillaume Richard, Marc A Dobrescu, Josée Bouchard, David Williamson, Dave Brindamour, Emmanuel Charbonney, Sébastien Dupuis. Refractory Dabigatran-Induced Hemorrhage Despite Multiple Idarucizumab Administration and Renal Replacement Therapy. Journal of pharmacy practice. 2022 Apr; 35(2):302-307. doi: 10.1177/0897190020961691. [PMID: 32985337]
  • Shumin Chen, Dongchun Cai, Yuzheng Lai, Jianfeng He, Qing Wu, Peichu Huang, Liang Zhou, Hao Sun. Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. Clinical neurology and neurosurgery. 2022 04; 215(?):107189. doi: 10.1016/j.clineuro.2022.107189. [PMID: 35231678]
  • Line D F Nielsen, Malthe Hansen-Bruhn, Minke A D Nijenhuis, Kurt V Gothelf. Protein-Induced Fluorescence Enhancement and Quenching in a Homogeneous DNA-Based Assay for Rapid Detection of Small-Molecule Drugs in Human Plasma. ACS sensors. 2022 03; 7(3):856-865. doi: 10.1021/acssensors.1c02642. [PMID: 35239321]
  • Cheng-Wei Cheng, Wen-Han Feng, Wei-Hua Tang, Hwang-Shang Kou, Chun-Chi Wang, Shou-Mei Wu. A three-step stacking capillary electrophoresis of field-amplified sample injection, sweeping, and micellar collapse for determination of dabigatran and its active metabolite in human plasma. Journal of food and drug analysis. 2022 Mar; 30(1):88-103. doi: 10.38212/2224-6614.3391. [PMID: 35647720]
  • Adane Teshome Kefale, Gregory M Peterson, Woldesellassie M Bezabhe, Luke R Bereznicki. Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data. Expert review of clinical pharmacology. 2022 Mar; 15(3):351-357. doi: 10.1080/17512433.2022.2044793. [PMID: 35184624]
  • Maureen A Smythe, Carly Burns, Qianyue Liu, Candice L Garwood. Potential Dexamethasone-Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?. The Annals of pharmacotherapy. 2022 03; 56(3):319-329. doi: 10.1177/10600280211025042. [PMID: 34137279]
  • T S Shahzada, C L Guo, A P W Lee. Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation. Hong Kong medical journal = Xianggang yi xue za zhi. 2022 Feb; 28(1):24-32. doi: 10.12809/hkmj209201. [PMID: 34737236]
  • Ray J Li, Gillian E Caughey, Sepehr Shakib. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation. Journal of thrombosis and thrombolysis. 2022 Feb; 53(2):425-435. doi: 10.1007/s11239-021-02528-x. [PMID: 34302286]
  • Izabela Zakrocka, Wojciech Załuska. Anticoagulant-related nephropathy: Focus on novel agents. A review. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2022 Feb; 31(2):165-173. doi: 10.17219/acem/142657. [PMID: 35212199]
  • Ozgur Karcioglu, Sehmus Zengin, Bilgen Ozkaya, Eylem Ersan, Sarper Yilmaz, Goksu Afacan, Derya Abuska, Mandana Hosseinzadeh, Selman Yeniocak. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal. Cardiovascular & hematological agents in medicinal chemistry. 2022; 20(2):103-113. doi: 10.2174/1871525719666210914110750. [PMID: 34521332]
  • Myrthe M A Toorop, Nienke van Rein, Melchior C Nierman, Helga W Vermaas, Menno V Huisman, Felix J M van der Meer, Suzanne C Cannegieter, Willem M Lijfering. Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. Journal of thrombosis and haemostasis : JTH. 2022 01; 20(1):92-103. doi: 10.1111/jth.15563. [PMID: 34664401]
  • Shin-Yi Lin, Ching-Hua Kuo, Tao-Min Huang, Yu-Fong Peng, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng. Impact of different renal function equations on direct oral anticoagulant concentrations. Scientific reports. 2021 12; 11(1):23833. doi: 10.1038/s41598-021-03318-4. [PMID: 34903821]
  • Emmanouela Kampouraki, Peter Avery, Tina Biss, Hilary Wynne, Farhad Kamali. Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients. British journal of haematology. 2021 12; 195(5):790-801. doi: 10.1111/bjh.17899. [PMID: 34658009]
  • Andrea Rubboli, Claudio Fresco, Maurizio Paciaroni, Bianca Rocca, Domenico Pecora, Iolanda Enea, Claudio Cuccia, Giuseppe Patti. How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. Journal of cardiovascular medicine (Hagerstown, Md.). 2021 Dec; 22(11):924-928. doi: 10.2459/jcm.0000000000001204. [PMID: 33927142]
  • A G Buenen, Marijn Sinkeldam, Martje L Maas, Martha Verdonschot, Peter C Wever. Prior use of anticoagulation is associated with a better survival in COVID-19. Journal of thrombosis and thrombolysis. 2021 Nov; 52(4):1207-1211. doi: 10.1007/s11239-021-02486-4. [PMID: 34061283]
  • Khurshid Shaikh, Ashish Mungantiwar, Supriya Halde, Nancy Pandita. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determination of free and total dabigatran in human plasma and its application to a pharmacokinetic study. Drug development and industrial pharmacy. 2021 Nov; 47(11):1835-1846. doi: 10.1080/03639045.2022.2069257. [PMID: 35452338]
  • T N Novikova. [Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function]. Kardiologiia. 2021 Oct; 61(10):81-88. doi: 10.18087/cardio.2021.10.n1767. [PMID: 34763642]
  • Arun Prabhahar Rajarajen, Raihan Ashraf, Nishtha Ahuja, Joyita Bharati. Extensive skin necrosis in an elderly woman on dabigatran. BMJ case reports. 2021 Oct; 14(10):. doi: 10.1136/bcr-2021-245245. [PMID: 34649859]
  • Katharina Thuile, Katia Giacomuzzi, Erika Jani, Peter Marschang, Thomas Mueller. Evaluation of the in vitro stability of direct oral anticoagulants in blood samples under different storage conditions. Scandinavian journal of clinical and laboratory investigation. 2021 Oct; 81(6):461-468. doi: 10.1080/00365513.2021.1946844. [PMID: 34278897]
  • Jennifer Lang, Ludwig Vincent, Marylore Chenel, Kayode Ogungbenro, Aleksandra Galetin. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2021 Oct; 165(?):105932. doi: 10.1016/j.ejps.2021.105932. [PMID: 34260894]
  • Ziv Harel, Eric McArthur, Nivethika Jeyakumar, Manish M Sood, Amit X Garg, Samuel A Silver, Paul Dorian, Daniel Blum, William Beaubien-Souligny, Andrew T Yan, Sunil V Badve, Brendan Smyth, Min Jun, Racquel Jandoc, Abhijat Kitchlu, Ron Wald. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clinical journal of the American Society of Nephrology : CJASN. 2021 10; 16(10):1470-1479. doi: 10.2215/cjn.05920421. [PMID: 34407990]
  • Thibaud Cavaillez, Laurent Weinmann, Christine Mouton, Céline Delassasseigne, Musa Sesay, Matthieu Biais, Chloé James, Stéphanie Roullet. A retrospective study of indications and consequences of monitoring direct oral anticoagulant plasma concentrations on patient care in a university hospital: The Retro-AOD study. Thrombosis research. 2021 Oct; 206(?):76-83. doi: 10.1016/j.thromres.2021.08.010. [PMID: 34419866]
  • Hiromi Kurokawa, Atsushi Taninaka, Hidemi Shigekawa, Hirofumi Matsui. Dabigatran Etexilate Induces Cytotoxicity in Rat Gastric Epithelial Cell Line via Mitochondrial Reactive Oxygen Species Production. Cells. 2021 09; 10(10):. doi: 10.3390/cells10102508. [PMID: 34685491]
  • In-Hwan Park, Jin-Woo Park, Hyewon Chung, Jong-Min Kim, Sangjin Lee, Kyoung-Ah Kim, Ji-Young Park. Development and validation of LC-MS/MS method for simultaneous determination of dabigatran etexilate and its active metabolites in human plasma, and its application in a pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2021 Sep; 203(?):114220. doi: 10.1016/j.jpba.2021.114220. [PMID: 34175734]
  • Akshay Athavale, Nazila Jamshidi, Darren M Roberts. Kidney dysfunction has a major impact on the effect of idarucizumab for dabigatran reversal. European journal of anaesthesiology. 2021 09; 38(9):1005-1006. doi: 10.1097/eja.0000000000001428. [PMID: 34397529]
  • Olivia S Costa, Bridget O'Donnell, Burcu Vardar, Khaled Abdelgawwad, Christopher W Brescia, Nitesh Sood, Craig I Coleman. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. Current medical research and opinion. 2021 09; 37(9):1493-1500. doi: 10.1080/03007995.2021.1947217. [PMID: 34166150]
  • Alethea Charlton, Xavier Vidal, Mònica Sabaté, Elena Bailarín, Lina María Leguízamo Martínez, Luisa Ibáñez. Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation. Journal of managed care & specialty pharmacy. 2021 Sep; 27(9):1210-1220. doi: 10.18553/jmcp.2021.27.9.1210. [PMID: 34464214]
  • Vincenzo Russo, Dario Cattaneo, Laura Giannetti, Roberta Bottino, Nunzia Laezza, Umberto Atripaldi, Emilio Clementi. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. Clinical therapeutics. 2021 09; 43(9):e255-e263. doi: 10.1016/j.clinthera.2021.07.003. [PMID: 34366151]
  • Jerrold H Levy, Joanne van Ryn, Frank W Sellke, Paul A Reilly, Amelie Elsaesser, Stephan Glund, Jörg Kreuzer, Jeffrey I Weitz, Charles V Pollack. Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Annals of surgery. 2021 09; 274(3):e204-e211. doi: 10.1097/sla.0000000000003638. [PMID: 31599808]
  • Agnieszka Kij, Anna Bar, Kamil Przyborowski, Bartosz Proniewski, Lukasz Mateuszuk, Agnieszka Jasztal, Anna Kieronska-Rudek, Brygida Marczyk, Karolina Matyjaszczyk-Gwarda, Anna Tworzydlo, Camilla Enggaard, Pernille B Lærkegaard Hansen, Boye Jensen, Maria Walczak, Stefan Chlopicki. Thrombin Inhibition Prevents Endothelial Dysfunction and Reverses 20-HETE Overproduction without Affecting Blood Pressure in Angiotensin II-Induced Hypertension in Mice. International journal of molecular sciences. 2021 Aug; 22(16):. doi: 10.3390/ijms22168664. [PMID: 34445374]
  • Jawad H Butt, Emil L Fosbøl, Peter Verhamme, Thomas A Gerds, Kasper Iversen, Henning Bundgaard, Niels Eske Bruun, Anders R Larsen, Andreas Petersen, Paal S Andersen, Robert L Skov, Gunnar H Gislason, Christian Torp-Pedersen, Lars Køber, Jonas B Olesen. Dabigatran and the Risk of Staphylococcus aureus Bacteremia: A Nationwide Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021 08; 73(3):480-486. doi: 10.1093/cid/ciaa661. [PMID: 32478836]
  • Gregory Y H Lip, Allison V Keshishian, Yan Zhang, Amiee Kang, Amol D Dhamane, Xuemei Luo, Christian Klem, Mauricio Ferri, Jenny Jiang, Huseyin Yuce, Steven Deitelzweig. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. JAMA network open. 2021 08; 4(8):e2120064. doi: 10.1001/jamanetworkopen.2021.20064. [PMID: 34398204]
  • Gurbaksh Singh Kanda, Wai Khoon Ho, Christopher Rodrigues, Anna Bousounis, Chris Hogan. Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran. Pathology. 2021 Aug; 53(5):623-627. doi: 10.1016/j.pathol.2020.10.017. [PMID: 33526243]
  • Sara Kutner, Nicholas Scaturo, Brett Williams. Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR). The American journal of emergency medicine. 2021 08; 46(?):800.e1-800.e3. doi: 10.1016/j.ajem.2021.01.086. [PMID: 33612323]
  • Brian W Gilbert, M Jacob Ott, George J Philip. Thromboelastography utilization for dabigatran reversal in a patient with acute kidney injury. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2021 07; 78(15):1382-1384. doi: 10.1093/ajhp/zxab182. [PMID: 33895798]
  • Brittney H Davis, Rajbeer Sangha, Chrisly Dillon, Todd M Brown, Renuka Narayan, Mark Beasley, Tom McElderry, Thomas D Nolin, Nita A Limdi. Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 07; 78(1):151-153. doi: 10.1053/j.ajkd.2020.09.018. [PMID: 33276038]
  • Mohamed Gamal El-Din Ewees, Mohamed Sadek Abdel-Bakky, Asmaa Mostafa Ahmed Bayoumi, Ali Ahmed Abo-Saif, Waleed Mohammad Altowayan, Khalid Saad Alharbi, Basim Anwar Shehata Messiha. Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway. Journal of advanced research. 2021 Jul; 31(?):127-136. doi: 10.1016/j.jare.2020.12.014. [PMID: 34194837]
  • Ingrid Škorňová, Matej Samoš, Tomáš Bolek, Alena Kamenišťáková, Lucia Stančiaková, Peter Galajda, Ján Staško, Peter Kubisz, Marián Mokáň. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study. Journal of cardiovascular pharmacology. 2021 07; 78(1):e122-e127. doi: 10.1097/fjc.0000000000001038. [PMID: 34173805]
  • Satoru Mitsuboshi, Takahiro Niimura, Yoshito Zamami, Keisuke Ishizawa. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. British journal of clinical pharmacology. 2021 07; 87(7):2977-2981. doi: 10.1111/bcp.14688. [PMID: 33270271]
  • Dawn Parsell, Jun Shao, Robert Guttendorf, Vandana Mathur, Elizabeth Li, Yick Sen Wu, Li Tsao, Scott Tabakman, Yuri Stasiv, Angela Lee, Kalpesh Biyani, Gerrit Klaerner. Assessment of the Potential for Veverimer Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals. 2021 07; 49(7):490-500. doi: 10.1124/dmd.121.000366. [PMID: 34031138]
  • Florian Härtig, Ingvild Birschmann, Andreas Peter, Matthias Ebner, Charlotte Spencer, Michael Gramlich, Hardy Richter, Joachim Kuhn, Rainer Lehmann, Gunnar Blumenstock, Christine S Zuern, Ulf Ziemann, Sven Poli. Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran. Thrombosis and haemostasis. 2021 Jun; 121(6):782-791. doi: 10.1055/s-0040-1721775. [PMID: 33469905]
  • Gabriello Marchetti, Francesco Bernardini, Michele Romoli, Stefano Urbinati. Switching across direct oral anticoagulants: a real-life-setting pilot prospective study. Journal of cardiovascular medicine (Hagerstown, Md.). 2021 06; 22(6):453-458. doi: 10.2459/jcm.0000000000001118. [PMID: 33186238]
  • Viktoria Muster, Thomas Gary, Reinhard B Raggam, Albert Wölfler, Marianne Brodmann. Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination. Lancet (London, England). 2021 05; 397(10287):1842. doi: 10.1016/s0140-6736(21)00871-0. [PMID: 33864749]
  • Qiuyi Ji, Chunyu Zhang, Qing Xu, Zi Wang, Xiaoye Li, Qianzhou Lv. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. British journal of clinical pharmacology. 2021 05; 87(5):2247-2255. doi: 10.1111/bcp.14646. [PMID: 33179295]
  • Klaus Grossmann. Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. International journal of molecular sciences. 2021 Apr; 22(9):. doi: 10.3390/ijms22094805. [PMID: 33946588]
  • Daniel Oberladstätter, Wolfgang Voelckel, Martin Bruckbauer, Johannes Zipperle, Oliver Grottke, Bernhard Ziegler, Herbert Schöchl. Idarucizumab in major trauma patients: a single centre real life experience. European journal of trauma and emergency surgery : official publication of the European Trauma Society. 2021 Apr; 47(2):589-595. doi: 10.1007/s00068-019-01233-y. [PMID: 31555877]
  • Hsin-Yu Chen, Shih-Hsiang Ou, Chien-Wei Huang, Po-Tsang Lee, Kang-Ju Chou, Pei-Chin Lin, Yi-Chia Su. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clinical drug investigation. 2021 Apr; 41(4):341-351. doi: 10.1007/s40261-021-01016-7. [PMID: 33709339]
  • Weniko Caré, Vincent Foissaud, Leslie Lefeuvre, Jean-Louis Daban, Dominique Vodovar, Marc Aletti, Caroline Doutrelon. Direct oral anticoagulant plasma level measurement in clinical practice: A French single-institution retrospective study. Thrombosis research. 2021 04; 200(?):83-86. doi: 10.1016/j.thromres.2021.01.021. [PMID: 33549898]
  • Walter Ageno, Ivan B Casella, Kok Han Chee, Sebastian Schellong, Sam Schulman, Daniel E Singer, Marc Desch, Wenbo Tang, Isabelle Voccia, Kristina Zint, Samuel Z Goldhaber. Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. Journal of thrombosis and thrombolysis. 2021 Apr; 51(3):561-570. doi: 10.1007/s11239-020-02239-9. [PMID: 32851572]
  • Emilia D'Elia, Mauro Gori, Aurelia Grosu, Annamaria Iorio, Ferdinando Luca Lorini, Anna Falanga, Fabiano Di Marco, Michele Senni. An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug. BMC pulmonary medicine. 2021 Mar; 21(1):102. doi: 10.1186/s12890-021-01453-2. [PMID: 33761886]
  • Mojca Božič Mijovski, Rickard E Malmström, Nina Vene, Jovan P Antovic, Alenka Mavri. The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation. Scientific reports. 2021 03; 11(1):5920. doi: 10.1038/s41598-021-85318-y. [PMID: 33723299]
  • T A Ruzhentsova, D A Khavkina, P V Chukhliaev, A A Garbuzov, A A Ploskireva. [Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients]. Voprosy virusologii. 2021 03; 66(1):40-46. doi: 10.36233/0507-4088-14. [PMID: 33683064]
  • Mohd Aslam Saifi, Shivaraju Annaldas, Chandraiah Godugu. A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1. European journal of pharmacology. 2021 Feb; 893(?):173838. doi: 10.1016/j.ejphar.2020.173838. [PMID: 33359646]
  • Ling-Lin Qian, Jing-Jing Ji, Jia-Qi Guo, Yan-Ping Wu, Gen-Shan Ma, Yu-Yu Yao. Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice. Clinical science (London, England : 1979). 2021 02; 135(3):447-463. doi: 10.1042/cs20201235. [PMID: 33458764]
  • Cynthia A Jackevicius, Lingyun Lu, Zunera Ghaznavi, Alberta L Warner. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation. Circulation. Cardiovascular quality and outcomes. 2021 02; 14(2):e007230. doi: 10.1161/circoutcomes.120.007230. [PMID: 33541109]
  • Tomáš Bolek, Matej Samoš, Lucia Stančiaková, Ingrid Škorňová, Kristína Grilusová, Peter Galajda, Ján Staško, Peter Kubisz, Marián Mokáň. The impact of atorvastatin on dabigatran plasma levels in patients with atrial fibrillation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2021 01; 32(1):69-71. doi: 10.1097/mbc.0000000000000979. [PMID: 33122496]
  • Juraj Sokol, Frantisek Nehaj, Jela Ivankova, Michal Mokan, Jana Zolkova, Lenka Lisa, Ludmila Linekova, Marian Mokan, Jan Stasko. Impact of Dabigatran Treatment on Rotation Thromboelastometry. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2021 Jan; 27(?):1076029620983902. doi: 10.1177/1076029620983902. [PMID: 33523711]
  • Ajay K Medipally, Min Xiao, Brad H Rovin, Anjali A Satoskar, Iouri Ivanov, Shahzeb Qaisar, Sergey V Brodsky. Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy. Physiological reports. 2021 01; 9(1):e14697. doi: 10.14814/phy2.14697. [PMID: 33427414]
  • Hongxia Li, Lei Zhang, Ming Xia, Chi Zhang, Tingbo Jiang. The Comparison of Therapeutic Efficacy Between Dabigatran Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2021 Jan; 27(?):10760296211044722. doi: 10.1177/10760296211044722. [PMID: 34559016]
  • S Mainbourg, M Cucherat, S Provencher, L Bertoletti, P Nony, F Gueyffier, P Mismetti, C Grange, I Durieu, R Kilo, S Laporte, G Grenet, J-C Lega. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. Thrombosis research. 2021 01; 197(?):24-32. doi: 10.1016/j.thromres.2020.10.011. [PMID: 33161284]
  • Karthik Lingineni, Nashid Farhan, Sarah Kim, Rodrigo Cristofoletti, Lori A Gordon, Parag Kumar, Scott Penzak, Colleen Hadigan, Jomy M George, Joshua D Brown, Stephan Schmidt. Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment. Clinical pharmacology and therapeutics. 2021 01; 109(1):193-200. doi: 10.1002/cpt.2087. [PMID: 33073366]
  • Imo J Akpan, Adam Cuker. Laboratory assessment of the direct oral anticoagulants: who can benefit?. Kardiologia polska. 2021; 79(6):622-630. doi: 10.33963/kp.a2021.0021. [PMID: 34029374]
  • Juan Lei, Yu Zhou, Huakan Zhao, Yu Chen, Guifang Yan, Lei Wu, Yanquan Xu, Jiangang Zhang, Xiao Zhang, Jingchun Wang, Dingshan Li, Yongsheng Li. Dabigatran activates inflammation resolution by promoting fibrinogen-like protein 2 shedding and RvD5n-3 DPA production. Theranostics. 2021; 11(9):4251-4261. doi: 10.7150/thno.50182. [PMID: 33754059]
  • Jacqueline Halton, Leonardo R Brandão, Matteo Luciani, Lisa Bomgaars, Elizabeth Chalmers, Lesley G Mitchell, Ildar Nurmeev, Anjali Sharathkumar, Pavel Svirin, Kirill Gorbatikov, Igor Tartakovsky, Monika Simetzberger, Fenglei Huang, Zhichao Sun, Jörg Kreuzer, Savion Gropper, Paul Reilly, Martina Brueckmann, Manuela Albisetti. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. The Lancet. Haematology. 2021 Jan; 8(1):e22-e33. doi: 10.1016/s2352-3026(20)30368-9. [PMID: 33290737]
  • Debnath Maji, Aman Opneja, Michael A Suster, Kara L Bane, Brigid M Wilson, Pedram Mohseni, Evi X Stavrou. Monitoring DOACs with a Novel Dielectric Microsensor: A Clinical Study. Thrombosis and haemostasis. 2021 Jan; 121(1):58-69. doi: 10.1055/s-0040-1715589. [PMID: 32877954]
  • Ahsan A Khan, Lewis J Hardy, Eduard Shantsila, Yee C Lau, Helen Philippou, Gregory Y H Lip. Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. Thrombosis research. 2021 01; 197(?):69-76. doi: 10.1016/j.thromres.2020.10.039. [PMID: 33189061]
  • Vera Paar, Peter Jirak, Susanne Gruber, Christine Prodinger, Janne Cadamuro, Bernhard Wernly, Lukas J Motloch, Elisabeth Haschke-Becher, Uta C Hoppe, Michael Lichtenauer. Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines - Slowing the vicious circle of coagulation and inflammation. Life sciences. 2020 Dec; 262(?):118474. doi: 10.1016/j.lfs.2020.118474. [PMID: 32961229]
  • Daniele Pastori, Evaristo Ettorre, Gregory Y H Lip, Angela Sciacqua, Francesco Perticone, Francesco Melillo, Cosmo Godino, Rossella Marcucci, Martina Berteotti, Francesco Violi, Pasquale Pignatelli, Mirella Saliola, Danilo Menichelli, Marco Antonio Casciaro, Vito Menafra. Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: A multicentre cohort study. British journal of clinical pharmacology. 2020 12; 86(12):2455-2463. doi: 10.1111/bcp.14350. [PMID: 32384178]
  • Bryan H Simpson, David M Reith, Natalie J Medlicott, Alesha J Smith. Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines. Journal of primary health care. 2020 12; 12(4):327-334. doi: 10.1071/hc19115. [PMID: 33349320]
  • Noel Chan, Magdalena Sobieraj-Teague, John W Eikelboom. Direct oral anticoagulants: evidence and unresolved issues. Lancet (London, England). 2020 11; 396(10264):1767-1776. doi: 10.1016/s0140-6736(20)32439-9. [PMID: 33248499]
  • Lars Wallentin, Johan Lindbäck, Niclas Eriksson, Ziad Hijazi, John W Eikelboom, Michael D Ezekowitz, Christopher B Granger, Renato D Lopes, Salim Yusuf, Jonas Oldgren, Agneta Siegbahn. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European heart journal. 2020 11; 41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697. [PMID: 32984892]
  • Elvira Grandone, Filippo Aucella, Doris Barcellona, Giuliano Brunori, Giacomo Forneris, Paolo Gresele, Marco Marietta, Daniela Poli, Sophie Testa, Armando Tripodi, Simonetta C Genovesi. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. Blood transfusion = Trasfusione del sangue. 2020 11; 18(6):478-485. doi: 10.2450/2020.0156-20. [PMID: 33000751]
  • V S Gorbatenko, A S Gerasimenko, O V Shatalova. [Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease]. Kardiologiia. 2020 Oct; 60(9):102-109. doi: 10.18087/cardio.2020.9.n1178. [PMID: 33131481]
  • E Rota, L Testa, G Di Brigida, S Agosti, M E Rovere, R Risso, N Morelli. The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm. Journal of thrombosis and thrombolysis. 2020 Oct; 50(3):732-738. doi: 10.1007/s11239-020-02108-5. [PMID: 32303943]
  • Maher M Aljohani, Raja Chinnappan, Omar A Alsager, Razan AlZabn, Ali Alhoshani, Karina Weber, Dana Cialla-May, Jürgen Popp, Mohammed Zourob. Mapping the binding region of aptamer targeting small molecule: Dabigatran etexilate, an anti-coagulant. Talanta. 2020 Oct; 218(?):121132. doi: 10.1016/j.talanta.2020.121132. [PMID: 32797889]
  • Marjorie Bernier, Sarah Line Lancrerot, Nadège Parassol, Thibaud Lavrut, Julien Viotti, Fanny Rocher, Milou-Daniel Drici. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit-Risk Ratio. Journal of cardiovascular pharmacology. 2020 10; 76(4):472-477. doi: 10.1097/fjc.0000000000000870. [PMID: 33030858]
  • Jingli Duan, Li Yang, Haiyan Li, Norio Yamamura, Akiko Harada. Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects. European journal of drug metabolism and pharmacokinetics. 2020 Oct; 45(5):601-609. doi: 10.1007/s13318-020-00626-4. [PMID: 32474728]
  • Xiaoxi Yao, Jonathan W Inselman, Joseph S Ross, Rima Izem, David J Graham, David B Martin, Aliza M Thompson, Mary Ross Southworth, Konstantinos C Siontis, Che G Ngufor, Karl A Nath, Nihar R Desai, Brahmajee K Nallamothu, Rajiv Saran, Nilay D Shah, Peter A Noseworthy. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation. Cardiovascular quality and outcomes. 2020 10; 13(10):e006515. doi: 10.1161/circoutcomes.120.006515. [PMID: 33012172]
  • Tingting Wu, Xiaotong Xia, Jinglan Fu, Wenjun Chen, Jinhua Zhang. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Medicine. 2020 Sep; 99(36):e22084. doi: 10.1097/md.0000000000022084. [PMID: 32899083]
  • Lina C Laxamana, Christian Oliver C Co, Jeryl Ritzi T Yu, Christianne V Mojica, Maria Adelaida M Iboleon-Dy, Alyssa Mae C Domingo, Karen Czarina S Ilano, Ma Cristina Z Macrohon-Valdez. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report. Clinical therapeutics. 2020 09; 42(9):1840-1845. doi: 10.1016/j.clinthera.2020.07.006. [PMID: 32778345]
  • Zining Wang, Xia Zhao, Pengkang He, Shuqing Chen, Jie Jiang, Akiko Harada, Steven Brooks, Yimin Cui. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. Advances in therapy. 2020 09; 37(9):3916-3928. doi: 10.1007/s12325-020-01439-2. [PMID: 32691242]
  • Maureen J M Werner, Jelle Adelmeijer, Vincent E de Meijer, Ruben H J de Kleine, René Scheenstra, Sander T H Bontemps, Koen M E M Reyntjens, Jan B F Hulscher, Robert J Porte, Ton Lisman. In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation. Thrombosis and haemostasis. 2020 Sep; 120(9):1240-1247. doi: 10.1055/s-0040-1713752. [PMID: 32629499]